Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid gains new substantial shareholder as director increases his interest to 6.4%

US-based Dennis Eck recently purchased a $1 million parcel of shares and now holds more than 5.331 million.
Jars with increasing amounts of cash
Cellmid is an Australian life sciences accelerator

Cellmid Ltd (ASX:CDY) has a new substantial shareholder with US-based non-executive director Dennis Eck now holding a 6.4% interest in the life sciences company.

Eck has this month acquired more than 2.63 million shares valued at $1 million, bringing the total number held to more than 5.331 million.

This acquisition follows one last December in which he acquired 2.7 million shares for total value of $1.026 million.

 

Eck’s confidence in the company is shared by other directors who have made recent purchases in a variety of ways.

These include on-market trades and participation in the recent share placement and share purchase plan (SPP).

Managing director and CEO Maria Halasz acquired 263,157 shares valued at for $100,000 while non-executive directors Bruce Gordon and Dr Martin Cross have made purchases valued at $10,000 and $50,400 respectively.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally.  

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

1534822132_cadoux.jpg
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
1530537220_Blood-Test.jpg
July 03 2018
The research and diagnostic company develops cancer-detecting blood tests
scientist with vial
August 09 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use